Sanofi to buy Inhibrx in $1.7 billion acquisition of trial therapy for rare disease AATD
MLex Summary: Sanofi has agreed to buy Inhibrx in a deal representing roughly $1.7 billion in value after the target spins off assets and liabilities not related to INBRX-101, the firm's...To view the full article, register now.
Already a subscriber? Click here to view full article